Roth Capital Reiterates Buy Rating for Can Fite Biopharma Ltd (CANF)
Separately, Rodman & Renshaw began coverage on Can Fite Biopharma in a research note on Monday, August 29th. They issued a “buy” rating and a $6.00 price objective for the company.
Can Fite Biopharma (NASDAQ:CANF) opened at 2.45 on Wednesday. The firm’s 50-day moving average is $2.50 and its 200 day moving average is $2.56. Can Fite Biopharma has a 1-year low of $1.85 and a 1-year high of $4.05. The stock’s market capitalization is $34.85 million.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/10/19/roth-capital-reiterates-buy-rating-for-can-fite-biopharma-ltd-canf.html
Can Fite Biopharma Company Profile
Can Fite Biofarma Ltd is an Israel-based biopharmaceutical company. The Company develops new treatments for autoimmune diseases and cancer. The Company’s drugs are CF101 for Psoriasis treatment, RA treatment, for the treatment of Keratoconjunctictivitis Sicca, for the treatment of Glaucoma, among others; and CF102 for the treatment of liver diseases.
Receive News & Ratings for Can Fite Biopharma Ltd Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Can Fite Biopharma Ltd and related companies with MarketBeat.com's FREE daily email newsletter.